Bionovo (BNVI) Reports Q3 Loss of $0.05
More News related to BNVI
- Biotech Stock Alert for Bionovo Inc. Issued by StockPreacher
- Morning Movers 01/14: ETRM, LAB, TSTR, CROX, HEB Higher; ROSG, MRNA, IPII, MED Lower
- Bionovo (BNVI) Published Phase 1B of Bezielle; Safe and Well Tolerated in Metastatic Breast Cancer Patients
- Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
- Dr. Marco Gambacciani, M.D. Joins Bionovo, Inc. Medical Advisory Board
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
Bionovo Inc. (NASDAQ: BNVI) reports Q3 EPS of $0.05 loss, in-line analyst estimate of ($0.05). Revenue for the quarter was $155K
Related Categories
EarningsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
